<DOC>
	<DOCNO>NCT00751790</DOCNO>
	<brief_summary>Efficacy safety triptorelin 6-month formulation patient advanced prostate cancer . It assume study treatment &gt; 90 % patient would achieve maintain castrate level serum testosterone .</brief_summary>
	<brief_title>Efficacy Safety Triptorelin 6-month Formulation Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>Efficacy triptorelin treatment gonadotropin ( LH ) stimulation hypophysis , well PSA ( prostate specific antigen ) level safety laboratory parameter . The triptorelin pharmacokinetics testosterone pharmacodynamics assess subset 15 patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Histologically cytologically proven prostate cancer . The prostate cancer stag T34NxMx TxN13Mx TxNxM1 accord TNM classification patient rise PSA fail local therapy candidate androgen deprivation therapy . Serum testosterone level &gt; 5 nmol/L . Karnofsky performance index &gt; 40 . Expected survival &gt; 18 month . Absence another malignancy , local dermatological , previous 5 year . Signed informed consent entry study . Prior hormonal treatment prostate cancer within 6 month prior study start . Use finasteride ( Proscar® ) dutasteride ( Avodart®/Avolve® ) within 2 month prior study start . Presence another neoplastic lesion brain metastasis . Prior hypophysectomy adrenalectomy . Known suspicion vertebral metastasis risk spinal compression . Severe kidney liver failure ( creatinine &gt; 2 time upper normal limit , ASAT ALAT &gt; 3 time upper normal limit ) . Any concomitant disorder result therapy likely interfere patient compliance study opinion Investigator . Participation another study experimental drug within 3 month study start within 5 drug halflives investigational drug ( whichever longer ) . Known hypersensitivity test material related compound . Known active use recreational drug alcohol dependence opinion Investigator . Any current use use within 6 month prior treatment start medication know affect metabolism and/or secretion androgenic hormone : ketoconazole , aminoglutethimide , oestrogen , progesterone . Use systemic inhaled corticosteroid ( topical application permit ) . Use anticoagulant : heparin coumarine derivative ( acetylsalicylic acid permit ) . Inability give Informed Consent comply fully protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>triptorelin , 6-month formulation , advanced prostate cancer</keyword>
</DOC>